Hutchmed
Nasdaq HCM · Hong Kong, Hong Kong
Works in Cardiovascular · Dermatology · GI & liver · Hematology · Immunology · Metabolic & endocrine · Oncology · Renal & urogenital · Respiratory · Women's health
Hutchmed is a clinical trial sponsor based in Hong Kong, Hong Kong, listed as Nasdaq HCM. It has 13 active clinical trials with 3,157 planned participants, across 10 therapeutic areas. Since 2021 it has completed 26 trials and stopped 9 early.
Trial track record · since 2021
Financials · Nasdaq HCM
Pipeline · 13 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Hutchmed
Hutchmed is lead sponsor of 13 active clinical trials on ClinicalTrials.gov, with 3,157 planned participants, in Cardiovascular, Dermatology, GI & liver, Hematology and other areas. Since 2021 it has completed 26 trials and stopped 9 early.
Hutchmed is based in Hong Kong, Hong Kong and is listed as Nasdaq HCM. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Hutchmed; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-01.
Approve Suite is not affiliated with Hutchmed.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.